Drug-eluting stents: A mechanical and pharmacologic approach to coronary artery disease

Pharmacotherapy

Volumn 24, Issue 11, 2004, Pages 1554-1577

  Dobesh, Paul P ^a,b   Stacy, Zachary A ^a,b   Ansara, Alexander J ^a,b   Enders, Jason M ^a,b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b ST LUKE S HOSPITAL   (United States)

Author keywords

Bare metal stents; Coronary artery disease; Drug eluting stents; Restenosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOPEPTIN; ANGIOTENSIN; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; CORTICOSTEROID; CYTOSTATIC AGENT; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; EVEROLIMUS; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; SEROTONIN; TACROLIMUS; THROMBIN; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; RESTENOSIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CLINICAL TRIALS; CORONARY DISEASE; CORONARY RESTENOSIS; FEMALE; HUMANS; MALE; PACLITAXEL; SIROLIMUS; STENTS;

EID: 7044262774     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.16.1554.50955     Document Type: Review

References (148)

1. Gruentzig A, Senning A, Siegenthaler W. Nonproliferative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
2. American Heart Association. 2003 heart and stroke statistical update. Dallas, TX: American Heart Association, 2002.
3. Popma JJ, Kuntz RE. Percutaneous coronary and valvular intervention. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia: WB Saunders, 2001:1364-405.
4. Holmes DR Jr, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77-81C.
5. Gruentzig AR, King SB III, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience. N Engl J Med 1987;316:1127-32.
6. Nobuyoshi M, Kimura T, Mosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-23.
7. Hirshfeld JW Jr, Schwartz JS, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18:647-56.
8. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6.
9. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal angioplasty. Circulation 1992;85:916-27.
10. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent: initial results of a multicenter study. Circulation 1991;83:148-61.
11. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
12. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6.
13. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA. A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. N Engl J Med 1997;336:817-22.
14. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med 1999;341:1957-65.
15. Bertiu A, Masotti M, Serra A, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four year follow-up. J Am Coll Cardiol 1999;34:1498-506.
16. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease: the BENESTENT study group. N Engl J Med 1994;331:489-95.
17. Ellis SG, Savage M, Fischman D, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: initial results of a multicenter experience. Circulation 1992;86:1836-44.
18. Martinez-Elbal L, Ruiz-Nodar JM, Zueco J, et al. Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. Direct stenting of coronary arteries. Eur Heart J 2002;23:633-40.
19. Ho KKL, Senerchia C, Rodriguez O, Chauhan MS, Kuntz RE. Predictors of angiographic restenosis after stenting: pooled analysis of 1197 patients with protocol-mandated angiographic follow-up from 5 randomized stent trials [abstr]. Circulation 1998;98:1-362.
20. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
21. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 2004;27:990-4.
22. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998;32:1610-18.
23. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length of restenosis after coronary stent placement. Am J Cardiol 1999;83:1617-22.
24. Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999;34:651-9.
25. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
26. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998;32:584-9.
27. Wurdeman RL, Hilleman DE, Mooss AN. Restenosis, the Achilles' heel of coronary angioplasty. Pharmacotherapy 1998;18(5):1024-40.
28. Kiesz RS, Buszman P, Martin JL, et al. Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial. Circulation 2001;103:26-31.
29. Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. Am J Med 2003;115:547-53.
30. Rodriguez AE, Palacios IF, Fernandez MA, Larribau M, Giraudo M, Ambrose JA. Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995;76(16):1131-4.
31. Mintz GS, Kent KM, Pichard AD, et al. Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Cardiol Clin 1997;15(1):17-29.
32. Shi Y, O'Brien JE, Fard A, Zalewski A. Transforming growth factor β1 expression and myofibroblast formation during arterial repair. Arterioscler Thromb Vasc Biol 1996;16:1298-305.
33. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30.
34. Komatsu R, Ueda M, Naruki T, et al. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological and immunohistochemical analyses. Circulation 1998;98:224-33.
35. Bennett MR, O'Sullivan M. Mechanism of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001;91:149-66.
36. Webb LMC, Ehrengruber MU, Clark-Lewis I, Baggiolini M. Binding to heparin sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 1993;90:7158-62.
37. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996;88:146-57.
38. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994;31:261-9.
39. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20.
40. Hawiger J. Adhesive interactions of blood cells and the vascular wall. In: Colman RW, Hirsch J, Marder VJ, Salzman ER, eds. Hemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia: JB Lippincott, 1994:762-96.
41. Bauters C, Isner JM. The biology of restenosis. In: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven, 1998:2465-90.
42. 2, and specific receptor antagonists on vascular smooth muscle proliferation. Circulation 1997;96:2280-6.
43. Chung IM, Gold HK, Schwartz SM, et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J Am Coll Cardiol 2002;40:2072-81.
44. Majeski MW, Lindner V, Twardzik DR, Reidy MA. Production of transforming growth factor beta-1 during repair of arterial injury. J Clin Invest 1991;88:904-10.
45. Rakugi H, Kim DK, Krieger JE, et al. Induction of angiotensin converting enzyme in the neointima after vascular injury: possible role in restenosis. J Clin Invest 1994;93:339-46.
46. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 1985;56:139-45.
47. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary stenting in patients with stable angina. Am J Cardiol 1998;82:515-18.
48. Weir L, Chen D, Pastore C, Isner JM, Walsh K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. J Biol Chem 1995;270:5457-61.
49. Braun-Dullaeus RC, von der Leyen HE, Mann MJ, Zhang L, Morris RE, Dzau VJ. Loss of p27Kip1 and induction of Ckd1 in the rat carotid artery following balloon catheter injury: in vivo and in vitro influence of rapamycin [abstr]. FASEB J 1997;11:A153.
50. Miano JM, Vlasic N, Tota RR, Stemerman MB. Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury: a putative in vivo mechanism for autocrine growth. Arterioscler Thromb 1993;13:211-19.
51. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
52. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug eluting stents: part I. Circulation 2003;107:2274-9.
53. Gilewski TA, Dang C, Sarborne A, Norton L. Principles of chemotherapy: cytokines. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer Medicine, 5th ed. Philadelphia: Lea and Febiger, 2000;11-38.
54. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Eng J Med 1995;32:1001-14.
55. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-76.
56. Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C, Wiernik PH. 20th Century advances in drug therapy in oncology: part II. Clin Pharm 2000;40:1079-925.
57. Food and Drug Administration. TAXUS EXPRESS™: paclitaxel-eluting coronary stent system. Available from http://www.fda.gov/ohrms/dockets/ac/03/ briefing/4005b1_03_ Labeling.pdf. Accessed February 27, 2004.
58. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application of stent restenosis. Circulation 2001;104:852-5.
59. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 2000;58:437-8.
60. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-17.
61. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
62. Gallo R, Padurean A, Chesebro JH, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by rapamycin. Circulation 1998;99:2164-70.
63. Hooks MA. Tacrolimus, a new immunosuppressant: a review of the literature. Ann Pharmacotherapy 1994;28(4):501-11.
64. Curfman GD. Sirolimus-eluting coronary stents. N Engl J Med 2002;346:1770-1.
65. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
66. Food and Drug Administration. CYPHER™ sirolimus-eluting coronary stent on RAPTOR® over-the-wire delivery system or RAPTORRAIL® rapid exchange delivery system-P020026. Available from http://www.fda.gov/cdrh/pdf3/ P020026c.pdf. Accessed Feb 27, 2004.
67. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-84.
68. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997;64:32-5.
69. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36-42.
70. Eisen HJ, Tuzco EM, Dorent R, et al. Everolimus for the prevention of graft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003;349:847-58.
71. Anonymous. Best of the ACC scientific session 2002. Rev Cardiovasc Med 2002;3:85-104.
72. Sievers TM, Rossi SJ, Ghobrial RM, et al. Mycophenolate mofetil. Pharmacotherapy 1997;17(6):1178-97.
73. Armstrong J, Gunn J, Arnold N, et al. Angiopeptin-eluting stents: observations in human vessels and pig coronary arteries. J Invasive Cardiol 2002;14:230-8.
74. Liu X, Huang Y, Hanet C, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60:172-8.
75. Berc BC, Gordon JB, Alexander RW. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol 1991;17(suppl B):111B-17.
76. New G, Moses JW, Roubin GS, et al. Estrogen-eluting, phosphorylcholine- coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model. Catheter Cardiovasc Inter 2002;57:266-71.
77. Geraldes P, Sirois MG, Bernatchez PN, et al. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2002;22:1585-90.
78. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
79. Schwartz RS, Edelman ER. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-73.
80. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation 2002;16:2859-66.
81. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part I. Circulation 2002;106:2734-40.
82. Honda Y, Grube E, de la Fuente LM, et al. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104(4):380-3.
83. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
84. Oberhoff M, Herdeg C, Baumbach A, Karsch KR. Stent-based antirestenotic coatings. Cath Cardio Interv 2002;55:404-8.
85. Hong MK, Mintz GS, Lee CW, et al. Intravascular ultrasound assessment of patterns of arterial remodeling in the absence of significant reference segment plaque burden in patients with coronary artery disease. J Am Coll Cardiol 2003;42(5):806-10.
86. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.
87. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8.
88. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
89. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
90. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
91. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003;41:184-9.
92. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107:24-7.
93. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
94. Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
95. Gershlick A, Scheerder ID, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting polymer free coronary stent: the European evaluation of paclitaxel-eluting stent (ELUTES) trial. Circulation 2004;109:487-93.
96. Grube E, Silber S, Hauptamann KE, et al. TAXUS 1: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
97. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stent for coronary artery lesions. Circulation 2003;108:788-94.
98. Tanabe K, Serruys PW, Grube E, et al. TAXUS III: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-64.
99. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
100. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22:2125-30.
101. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
102. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-13.
103. Sousa JE, Costa MA, Sousa A, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.
104. Sousa JE. Long-term follow-up, additional subset analysis and final perspective: the FIM 4-year results. Presented at the 53rd annual scientific session of the American College of Cardiology, New Orleans, LA, March 6, 2004.
105. Pharmaceutical Product Development, Inc. The drug-eluting stent summit-part 1. RAVEL 2-year follow-up. Available from http://www.tctmd.com/ display/expert/pdf/95099/Morice-DESS.pdf. Accessed March 24, 2004.
106. Dussaillant GR, Mintz GS, Pichard AD, et al. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. J Am Coll Cardiol 1995;26:720-4.
107. Costa MA, Sabate M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-92.
108. The ERASER Investigators. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER group). Circulation 1999;100:799-806.
109. Sousa JE. Three-year follow-up of the first-in-man patients: are there any late concerns? Presented at the 52nd annual scientific session of the American College of Cardiology, Chicago, IL, March 29, 2003.
110. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 202;106:798-803.
111. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting BX velocity balloon-expandable stent (RAVEL). Sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949-56.
112. Tanabe K, Serruys PW, Degertekin M, et al. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. Am J Cardiol 2002;90:937-41.
113. Pharmaceutical Product Development, Inc. Three-year follow-up of RAVEL. Available from http://www.tctmd.com/display/expert/pdf/103610/RAVEL-ACC04.pdf. Accessed March 24, 2004.
114. Kereiakes D, Moses JW, Leon MB, et al. Durable clinical benefit following CYPHER coronary stent deployment: SIRIUS study 2-year results [abstr]. Circulation 2003; 108(suppl IV):IV-532.
115. Cannon CP, Weintraub WB, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
116. Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up on the FRISC II invasive study. J Am Coll Cardiol 2002;40:1902-14.
117. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the rapamycin-eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-9.
118. Conceptis Technologies. RESEARCH: 12-month safety and efficacy data presented for off-label use of CYPHER stent. Available from http://www.theheart. org/viewEntityDispatcher Action.do?primaryKey=441209. Accessed March 24, 2004.
119. Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation 2003;108:1927-9.
120. Conceptis Technologies. Zero restenosis with paclitaxel-coated stent at nine months. Available from http://www. theheart.org/documents/page.cfm?from= 590001200&doc_id=27887. Accessed March 24, 2004.
121. Stone GW, Ellis SG, Cox DA, et al. The pivotal U.S. study of the slow-rate release polymer-based paclitaxel-eluting TAXUS stent in patients with de novo coronary lesions: 1-year clinical results of the TAXUS-IV trial [abstr]. Circulation 2003;108(suppl IV):IV-533.
122. Hong MK, Mintz GS, Lee CW, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian paclitaxel-eluting stent clinical trial (ASPECT). Circulation 2003;107:517-20.
123. Honda Y, Grube E, de la Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380-3.
124. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implanted for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002;105:1883-6.
125. Kataoka T, Grube E, Honda Y, et al. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 2002;106:1788-93.
126. Conceptis Technologies. Longer-term data on sirolimus and paclitaxel stents, plus newcomer to the stent: EASTER. Available from http://www.theheart. org/viewWeblink.do?wLprimaryKey=346459. Accessed March 24, 2004.
127. Conceptis Technologies. No lasting IMPACT from mycophenolic-acid-coated stent trial, while EASTER hunt will continue with estrogen-dipped stents. Available from http://www.theheart.org/documents/page.cfm?from=59001200 &doc_id=36002. Accessed March 24, 2004.
128. Costa RA, Lansky A, Mehran R, et al. Everolimus-eluting stent for the treatment of de novo coronary lesions: angiographic follow-up of the FUTURE trial. Presented at the 76th annual scientific sessions of the American Heart Association, Chicago, IL, November 12, 2003.
129. Grube E. Late breaking clinical trials: FUTURE I and FUTURE II. Presented at the 15th annual transcatheter cardiovascular therapeutics conference, Washington, DC, September 17, 2003.
130. Meredith I. ENDEAVOR I: multicenter evaluation of ABT-578 elution from a phosphorylcholine-coated stent, 4-month angiographic and IVUS follow-up. Presented at the 15th annual transcatheter cardiovascular therapeutics conference, Washington, DC, September 17, 2003.
131. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-93.
132. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-703.
133. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000;101:2165-71.
134. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-6.
135. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary stenting. N Engl J Med 1998;339:1665-71.
136. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
137. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1998;96:636-45.
138. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
139. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo controlled trial. Lancet 2000;356:2037-44.
140. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
141. Moussa I, Leon MB, Mehran R, et al. The impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcome of diabetic patients undergoing sirolimus-eluting versus bare metal stent implantation: results from the SIRIUS Trial [abstr]. Am J Cardiol 2003;92(suppl 6A):91L.
142. O'Shea JC, Buller CR, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287:618-21.
143. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet 1999;354:2019-24.
144. Lincoff AM, Bittl JA, Harrington RA, et al. The REPLACE 2 trial: bivalirudin and provisional glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 2003;289:853-63.
145. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction 2002; summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002;106:1893-900.
146. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
147. Leon MB, Bakhai A. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. Am Heart J 2003;146:S13-17.
148. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus drug-eluting stents for treatment of complex coronary stenoses: results from the SIRIUS trial. Presented at the 52nd annual scientific sessions of the American College of Cardiology, Chicago, IL, March 30, 2003.